Literature DB >> 23334511

Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.

Saby George1, Roberto Pili.   

Abstract

Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23334511     DOI： 10.1007/s11912-013-0295-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  20 in total

1.  The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.

Authors:  Susan L Dalrymple; Robin E Becker; John T Isaacs
Journal:  Prostate       Date:  2007-05-15       Impact factor: 4.104

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

Review 3.  End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

Authors:  Howard I Scher; Michael J Morris; Ethan Basch; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

Authors:  John T Isaacs; Roberto Pili; David Z Qian; Susan L Dalrymple; Jason B Garrison; Natasha Kyprianou; Anders Björk; Anders Olsson; Tomas Leanderson
Journal:  Prostate       Date:  2006-12-01       Impact factor: 4.104

7.  Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.

Authors:  Anders Olsson; Anders Björk; Johan Vallon-Christersson; John T Isaacs; Tomas Leanderson
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

8.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

9.  S100A9 interaction with TLR4 promotes tumor growth.

Authors:  Eva Källberg; Thomas Vogl; David Liberg; Anders Olsson; Per Björk; Pernilla Wikström; Anders Bergh; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

10.  Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

Authors:  O Bratt; M Häggman; G Ahlgren; O Nordle; A Björk; J-E Damber
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640
View more
  3 in total

Review 1.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model.

Authors:  Soňa Jantová; Dominika Topoľská; Michaela Janošková; Miroslav Pánik; Viktor Milata
Journal:  Interdiscip Toxicol       Date:  2017-05-17

3.  Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse.

Authors:  Sahar Tahvili; Marie Törngren; Dan Holmberg; Tomas Leanderson; Fredrik Ivars
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.